Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 2,832,000 shares, a decline of 42.3% from the June 15th total of 4,910,000 shares. Based on an average daily trading volume, of 5 shares, the days-to-cover ratio is currently 566,400.0 days.
Genscript Biotech Stock Performance
OTCMKTS GNNSF remained flat at C$1.50 during trading hours on Thursday. Genscript Biotech has a 1 year low of C$1.30 and a 1 year high of C$2.42. The company’s 50 day moving average price is C$1.63 and its 200 day moving average price is C$1.63.
Genscript Biotech Company Profile
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
See Also
- Five stocks we like better than Genscript Biotech
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
